Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need
Author: brian@
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only formulation
VenatoRx Pharmaceuticals Initiates Enrollment in Phase 3 Trial of Cefepime/VNRX-5133 in Patients with Complicated Urinary Tract Infections
Demonstrated potent activity against carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Pseudomonas aeruginosa
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
BOSTON, Aug. 26, 2019 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at Baird’s 2019 Global Healthcare Conference on Wednesday, September 4 at 3:10 p.m. ET at the InterContinental New York Barclay in New York.
VenatoRx Pharmaceuticals Expands Development Team as It Advances Its Antibacterial and Antiviral Portfolio
MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today announced the addition of pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta to its development team. These appointments come as the Company continues to advance its portfolio of antibacterial and antiviral assets through their respective pre-clinical and clinical milestones.
Cidara Therapeutics to Present Data from its Cloudbreak Antiviral Program at the Options X for the Control of Influenza Conference
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore.
SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
Significant progress made in Phase 3 VANISH program evaluating oral ibrexafungerp for the treatment of VVC, with NDA submission anticipated in the second half of 2020
Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20...
Entasis Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
WALTHAM, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the 2019 Wedbush PacGrow Healthcare Conference being held August 13-14,...
VenatoRx Pharmaceuticals named ‘Best Places to Work’ Second Year in a Row
MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today announced that it was named one of the “2019 Best Places to Work” in the Greater Philadelphia area by the Philadelphia Business Journal.